U.S. Packaging Stock News

Pebblebrook Hotel Trust (NYSE:PEB) recently completed a $450 million senior unsecured term loan. The company used part of the proceeds to repay certain mortgages and address near term debt maturities. Management also restored full capacity on its revolving credit facility, increasing available liquidity. Pebblebrook Hotel Trust, trading at $12.24, has had mixed share performance, with a 6.0% return year to date and a 4.6% return over the past year, but weaker 3 year and 5 year returns of...

If you are wondering whether Perfect's current share price reflects its true worth, this breakdown will help you connect the recent market action to what the numbers actually say about value. Perfect's share price closed at US$1.38, with returns of a 5.5% decline over 7 days, a 17.4% decline over 30 days, a 20.2% decline year to date, a 27.7% decline over 1 year and 81.9% and 86.1% declines over 3 and 5 years. This performance sits against a backdrop of ongoing market attention on software...

ONEOK (NYSE:OKE) reported double digit net income and adjusted EBITDA growth for 2025. The company exceeded synergy targets from recent acquisitions, including Magellan, and retired a significant amount of long term debt. ONEOK raised its quarterly dividend by 4% and continued integrating acquired assets through 2025. Management outlined plans for 2026 that include expansion into fee based earnings and energy solutions for data centers. ONEOK is a large midstream operator focused on natural...

What Avidity Biosciences’ Recent Returns Signal for Investors Avidity Biosciences (RNA) has drawn attention after a 1 day return close to flat, modest moves over the past week and month, and a very large total return over the past year. For investors, those figures sit alongside a revenue base of US$18.755 million and a reported net loss of US$684.631 million. This highlights that the company remains firmly in a development focused phase. See our latest analysis for Avidity Biosciences. With...

Day One Biopharmaceuticals (DAWN) just reported its FY 2025 numbers, with Q4 total revenue of US$53.7 million and a net loss of US$21.3 million, setting the tone for how investors will read the year as a whole. The company has seen quarterly revenue move from US$29.2 million in Q4 2024 to US$53.7 million in Q4 2025, while Basic EPS shifted from a loss of US$0.64 per share in Q4 2024 to a loss of US$0.19 per share in Q3 2025, giving investors a clear view of how top line scale and loss levels...

First Citizens BancShares (FCNCA) has wrapped up FY 2025 with Q4 total revenue of US$2.4b and basic EPS of US$45.78, alongside net income of US$566m that feeds into a trailing 12 month net profit margin of 23.8%, compared with 29.1% a year earlier. Over recent periods, the bank has seen total revenue move between US$2.1b and US$2.4b per quarter and quarterly EPS range from US$34.47 to US$49.18. This gives investors a clear set of numbers to weigh against a five year earnings growth rate of...

If you are wondering whether Air Lease is still offering value at its current share price, this article will walk through what the numbers actually say about the stock. With the share price at US$64.85 and returns of 0.1% over 7 days, 0.7% over 30 days, 1.1% year to date, 36.8% over 1 year, 57.7% over 3 years and 50.1% over 5 years, many investors are asking whether expectations and valuation are now in sync. Recent news on Air Lease has focused on its role in supplying aircraft to airlines...

In the past quarter, Gladstone Land Corporation reported fourth-quarter 2025 sales of US$41.45 million and net income of US$4.21 million, alongside full-year 2025 revenue of US$88.34 million and net income of US$13.53 million. The sharp year-over-year improvement in quarterly sales and earnings contrasts with softer full-year sales, highlighting how recent operational performance may be shifting for this farmland-focused REIT. Next, we’ll consider how this strong quarterly earnings growth,...

Twist Bioscience, NasdaqGS:TWST, has entered a co exclusive licensing agreement with Invenra Inc. for Invenra's B Body bispecific antibody platform. The deal expands Twist's antibody discovery services and includes an equity investment and licensing terms that share economics between the two companies. This move adds bispecific antibody capabilities to Twist's existing biologics discovery tools, broadening the range of programs it can support for biotech and pharma customers. Twist...

Analysts are flagging anticipated revenue declines for Fortive, citing softer demand and slower organic growth expectations. This shift in sentiment follows previously solid quarterly results and points to a possible inflection in the company’s operational outlook. The change comes as investors reassess Fortive’s near term growth profile beyond recent share price moves. For investors watching Fortive, ticker NYSE:FTV, the backdrop is a mix of steady share performance and growing questions...

Array Digital Infrastructure (NYSE:AD) has completed a transformation by selling its wireless operations and related spectrum assets. The company transferred spectrum holdings to major carriers, including T-Mobile and AT&T, and repositioned itself as a focused tower operator. Array Digital Infrastructure secured new long term Master License Agreements with top telecom companies for tower usage. The company distributed special dividends and outlined plans to invest further in its...

Bank of Hawaii (NYSE:BOH) has announced that its CEO plans to retire at the end of March 2026. A board member recently executed a substantial sale of Bank of Hawaii shares. These leadership and ownership changes come as the stock last closed at $76.83. For investors watching Bank of Hawaii, the combination of a planned CEO retirement and a large board member share sale puts the focus squarely on governance and continuity. NYSE:BOH last closed at $76.83, with the stock showing returns of...

Vaxcyte (NasdaqGS:PCVX) has launched a comprehensive Phase 3 adult clinical program for its VAX-31 pneumococcal conjugate vaccine. The company has completed enrollment in a Phase 2 study of VAX-31 in infants. Vaxcyte is preparing to advance a separate vaccine candidate targeting Group A Streptococcus. These moves follow FDA alignment and an expanded Breakthrough Therapy designation for VAX-31. Vaxcyte, trading at about $61.35, is moving into a more mature stage of its pipeline, with VAX-31...

Oncolytics Biotech (ONCY) has attracted fresh attention after a recent move in its share price, with the stock closing at US$1.13 and showing mixed return patterns across the past year and over multiple years. See our latest analysis for Oncolytics Biotech. The recent 6.6% 1 day share price return and 10.8% 7 day share price return suggest short term momentum is building around Oncolytics Biotech, even as the 58.3% 1 year total shareholder return contrasts with weaker 3 and 5 year total...

Preferred Bank reclassified a sizable loan relationship from substandard to nonaccrual status following ongoing legal complications involving the borrower’s principals. The borrower is facing complex lawsuits that have contributed to cash flow pressures and payment issues on the loan. Management has indicated that, based on current expectations, the ultimate resolution of this credit is not expected to significantly affect 2026 earnings. For you as an investor following NasdaqGS:PFBC, this...

The Morning Bull - US Market Morning Update Wednesday, Feb, 25 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.1% and Nasdaq-100 futures ahead by roughly 0.2%, as investors weigh stronger hiring against easier borrowing costs. Fresh figures from ADP show private employers adding around 12,750 jobs a week over the past month, the fastest pace since late November, which signals companies are still hiring and paychecks are still flowing...

If you are trying to work out whether OneStream is attractively priced or not, this article will walk through what its current valuation might be telling you. With the share price at US$23.48 and returns of 0.4% over 7 days, a 0.6% decline over 30 days and 32.5% year to date, OneStream has caught the eye of investors who are watching how sentiment could be shifting. Recent coverage has focused on OneStream as part of the broader conversation around software names, which helps explain why...

FDA milestones put Larimar Therapeutics (LRMR) and nomlabofusp in sharper focus Larimar Therapeutics (LRMR) is back on investors’ radar after the FDA granted Breakthrough Therapy Designation to its Friedreich's ataxia candidate nomlabofusp and signaled openness to a surrogate endpoint supporting a potential accelerated approval filing. See our latest analysis for Larimar Therapeutics. The FDA update has arrived alongside a sharp pickup in momentum, with a 1 day share price return of 31.32%...

In February 2026, Clean Energy Fuels reported fourth-quarter 2025 results showing revenue of US$112.32 million and a wider net loss of US$43.00 million, alongside guidance for a 2026 net loss attributable to the company of US$71.00 million to US$66.00 million, excluding unrealized contract impacts and estimated US$47.00 million of Amazon warrant charges. The company also flagged that swings in diesel and natural gas markets, plus variations in Amazon warrant vesting, could materially alter...

Lindsay (NYSE:LNN) has introduced two new safety products, the Road Runner Truck-Mounted Attenuator and the AlphaGuard Channelizing Device. The products expand the company’s roadway and work zone safety lineup, targeting construction and traffic management applications. Both launches focus on work zone protection, operational efficiency, and evolving infrastructure management needs. Lindsay, trading at $135.74, is building on its position in roadway and infrastructure safety with these new...

If you are wondering whether PicS is attractively priced at its recent levels, this article will walk through what the current numbers are really saying about the stock. The share price recently closed at US$16.81, with a 7 day return of 27.4% and a year to date return of an 11.5% decline. This has caught the attention of investors who are considering the balance between growth potential and risk. Recent news coverage around PicS has focused on its positioning within the diversified...

Pamela Seymon and former CEO Sharmistha Dubey plan to leave Match Group's Board at the 2026 Annual Meeting. The departures will change the board composition at NasdaqGS:MTCH and affect its governance structure. Investors are watching for how these board changes may influence oversight and long term company direction. Match Group, the parent of several online dating platforms, sits at the center of how people form relationships through digital services. As user behavior, regulation, and...

Select Medical Holdings (NYSE:SEM) has received a nonbinding indication of interest to take the company private. A special committee of the Board is currently reviewing the proposal. The approach represents a potential change in ownership structure and corporate control. For shareholders, the timing of this approach comes after a mixed share price record. The stock closed at $14.82, with a 1-year return of a 21.3% decline and a 3-year return of a 6.6% decline. Over 5 years, the share price...

Harmonic has agreed to sell its Video business to MediaKind, repositioning itself as a pure-play broadband company. The company is integrating its broadband technology with ATX Networks to support cable operators upgrading their networks. A multi-year agreement with izzi in Mexico targets large scale fiber expansion using Harmonic solutions. Harmonic, ticker NasdaqGS:HLIT, is refocusing around broadband at a time when its shares trade at $10.44. The stock shows mixed longer term...